By now you’ve read the headlines about the high cost of the new cholesterol lowering drugs. We’ve been bombarded with commentary, articles and opinion pieces on these drugs and their high prices. The PCSK9 inhibitors – injectable, biologic drugs that dramatically lower LDL-cholesterol – appear to be very efficacious. But these drugs are priced at… Read More
This past weekend Esperion participated, for the 15th year, in the American Heart Association’s (AHA) annual Heart Walk to raise money for cardiovascular disease research. It is hard for me to put into words the inspiring nature of these events – as patients, survivors, doctors and others join together to combat what continues to be… Read More
This brief video blog features April Seiler, Esperion’s Director of Project Management. In this video, April describes how she has experienced the evolution of ETC-1002 and Esperion 2.0, and her insight into the future of Esperion.
This brief video blog features Diane MacDougall, Esperion’s Director of Clinical Development. In this video Diane shares her excitement for drug development and passion for ETC-1002 and her work at Esperion.
One year ago today the “new” Esperion re-entered the public markets with an initial public offering that raised $80 million and with a singular focus: to rapidly advance the development of ETC-1002, a unique, first-in-class, oral, once-daily low-density lipoprotein cholesterol (LDL-C) lowering therapy for patients with hypercholesterolemia who are unable to tolerate a statin. Since… Read More
As members of the Esperion team developing ETC-1002—a unique, first-in-class, orally available, once-daily small molecule designed to lower low density lipoprotein cholesterol (LDL-C) levels, particularly in individuals with hypercholesterolemia who are intolerant to statins—we are excited any time there is a specific emphasis on, or a new development in, this underserved patient population. In the… Read More